Alzheimer’s Blood Tests

What investment is rudimentary for billionaires but ‘revolutionary’ for 70,571+ investors entering 2026?

Imagine this. You open your phone to an alert. It says, “you spent $236,000,000 more this month than you did last month.”

If you were the top bidder at Sotheby’s fall auctions, it could be reality.

Sounds crazy, right? But when the ultra-wealthy spend staggering amounts on blue-chip art, it’s not just for decoration.

The scarcity of these treasured artworks has helped drive their prices, in exceptional cases, to thin-air heights, without moving in lockstep with other asset classes.

The contemporary and post war segments have even outpaced the S&P 500 overall since 1995.*

Now, over 70,000 people have invested $1.2 billion+ across 500 iconic artworks featuring Banksy, Basquiat, Picasso, and more.

How? You don’t need Medici money to invest in multimillion dollar artworks with Masterworks.

Thousands of members have gotten annualized net returns like 14.6%, 17.6%, and 17.8% from 26 sales to date.

Explore offerings

_{*Based on Masterworks data. Past performance is not indicative of future returns. Important Reg A disclosures: masterworks.com/cd}

A wave of new research is accelerating the development of blood tests capable of detecting Alzheimer’s‑related biomarkers long before symptoms appear. Scientists are finding that certain proteins associated with the disease can be measured in the bloodstream with increasing accuracy, offering a potential breakthrough in early diagnosis.

Traditionally, Alzheimer’s detection has relied on brain imaging or spinal fluid tests — procedures that are expensive, invasive, or difficult to access. Blood‑based diagnostics could change that entirely. Early detection allows patients and families to plan ahead, begin supportive therapies sooner, and participate in clinical trials that may slow disease progression.

Still, experts caution that these tests are not perfect. Biomarkers can indicate risk, but they don’t always predict who will develop symptoms. Researchers are working to refine accuracy and determine how best to integrate these tests into routine care.

If validated at scale, blood‑based Alzheimer’s screening could become one of the most significant public‑health tools of the decade — offering earlier answers, better planning, and more equitable access to diagnosis.